Beth Israel Deaconess Medical Center

Boston, MA

Filters

Sort by

Not currently accepting

KarMMa-2

Phase 2 Clinical Trial Studying the Safety and Efficacy of bb2121 in Participants with Relapsed and Refractory Multiple Myeloma or Clinical High-Risk Multiple Myeloma

Learn more

CAR T Cell
BCMA
High Risk
Phase 2

Not yet accepting

A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma and Determine the Recommended Dose for Each Add-on Investigational Component

Learn more

CAR T Cell
CELMoD
GPRC5D
Phase 1

Get personalized results in 60 seconds

All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.

Help me find trials

Accepting patients

Daratumumab Combination Therapy

Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

Learn more

Monoclonal Antibody
Proteasome Inhibitor
CD38
Phase 2

Not yet accepting

Elranatamab as Consolidation

A Phase 2 Study of Elranatamab as Consolidation After Idecabtagene Vicleucel in Relapsed Refractory Multiple Myeloma

Learn more

Bispecific Antibody
BCMA
CD3
Phase 2

Not yet accepting

Elotuzumab + Iberdomide Post ABECMA

Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM

Learn more

Monoclonal Antibody
SLAMF7
Phase 1/2

Not yet accepting

CARTITUDE-6

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (CARTITUDE-6)

Learn more